Group One Trading, L.P. Oncternal Therapeutics, Inc. Transaction History

Group One Trading, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	BUY	$0.7 - $1.56 $12,184 - $27,153	17,406 Added 514.21%	20,791 $23,000
Q1 2022 May 12, 2022	SELL	$1.37 - $2.43 $7,835 - $13,897	-5,719 Reduced 62.82%	3,385 $5,000
Q4 2021 Feb 11, 2022	BUY	$2.27 - $4.39 $20,666 - $39,966	9,104 New	9,104 $21,000
Q3 2021 Nov 12, 2021	SELL	$3.37 - $4.76 $119,277 - $168,475	-35,394 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$4.75 - $9.39 $46,070 - $91,073	9,699 Added 37.75%	35,394 $168,000
Q1 2021 May 12, 2021	BUY	$4.59 - $9.04 $117,063 - $230,556	25,504 Added 13352.88%	25,695 $214,000
Q3 2019 Nov 12, 2019	BUY	$3.87 - $6.13 $739 - $1,170	191 New	191 $1,000

362K

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $29.4M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.